Importing medicinal products into the UK requires a robust quality framework to ensure compliance with MHRA GMP requirements. For pharmaceutical companies, Marketing Authorisation Holders (MAHs), and overseas manufacturers, effective UK MIA importation testing is a critical part of ensuring product quality, regulatory compliance, and timely market supply.
At Sciom, we support global pharmaceutical companies with comprehensive UK importation testing services, quality control testing, documentation review, and QP release UK support to help ensure imported medicinal products meet regulatory expectations before reaching patients.
Our integrated approach combines analytical expertise, quality systems, and regulatory knowledge to provide reliable pharmaceutical batch release services across a wide range of dosage forms.
What is UK MIA Importation?
A UK Manufacturing and Import Authorisation (MIA) holder is responsible for ensuring that imported medicinal products meet the requirements of UK GMP before certification by the Qualified Person (QP) and release for supply.
In accordance with the principles outlined in Annex 21 – Importation of Medicinal Products, importers must establish appropriate procedures to ensure that imported medicinal products are manufactured, tested, stored, and handled in compliance with the Marketing Authorisation, GMP requirements, and applicable regulatory expectations.
Common Challenges during Importation of Products:
1. Understanding UK GMP Importation Requirements
The Challenge
Many companies entering the UK market are unfamiliar with the specific requirements associated with pharmaceutical importation.
Common questions include:
- What testing is required after importation?
- previous overseas testing be accepted?
- Do they need to Sampling at UK site or CMO site?
- What documentation is required for QP release?
- How can testing timelines be managed efficiently?
Failure to establish the correct importation strategy can result in unnecessary testing, supply delays, or regulatory concerns.
How Sciom Supports
Sciom provides a structured approach to UK MIA importation to batch Release, including:
- Regulatory requirement evaluation
- Specification review
- Quality documentation review
- Defined Process from Importation to Batch Release.
Our experienced quality and technical teams work with clients to establish a compliant and practical pathway for UK product supply.
2. Delays in Pharmaceutical Batch Release
The Challenge
Timely batch release is critical to maintaining medicine supply continuity while ensuring all required quality activities are completed in accordance with UK GMP requirements.
Pharmaceutical companies can experience delays in the batch release process due to:
- Limited laboratory capacity or complex testing
- Multiple testing providers (QC and Microbiology separate)
- Delays in receiving analytical results and supporting documentation
- Incomplete or inconsistent batch documentation
- Unexpected analytical challenges, investigations, or quality events
- Limited visibility of testing progress and release readiness
These challenges can impact supply planning, increase operational complexity, and delay the Qualified Person (QP) certification and release process.
How Sciom Supports
Sciom provides an integrated pharmaceutical testing and batch release support solution designed to simplify quality operations and improve release timelines.
Our approach includes:
- Integrated QC and Microbiology testing capabilities within one controlled quality environment
- Efficient testing workflows to support faster turnaround times and timely availability of quality data
- Client Portal access providing real-time visibility of project progress, documentation, and batch status
- Proactive project planning and coordination to ensure testing activities align with supply requirements
- Comprehensive quality documentation support to assist QP assessment and batch certification activities
By managing testing activities, quality documentation, and communication through a controlled and transparent process, Sciom helps companies reduce avoidable delays and achieve a more efficient, compliant batch release pathway.
3. Analytical Method Transfer Challenges
The Challenge
Imported products are often supported by analytical methods developed at overseas manufacturing facilities.
However, challenges may arise due to:
- Differences in analytical instruments
- Method suitability issues
- Variations in laboratory conditions
- Incomplete technical transfer packages
How Sciom Supports
Sciom provides analytical support including:
- Analytical method review
- Method transfer
- Gap Assessment against MHRA guidance
- Nitrosamine Testing (if required)
Our scientific team ensures analytical methods are suitable for implementation within a UK GMP laboratory environment.
4. Supporting QP Release UK Requirements
The Challenge
The Qualified Person (QP) is responsible for certifying that each batch of medicinal product complies with UK GMP requirements, the Marketing Authorisation, and Annex 16 principles before the batch is released for supply.
For imported medicinal products, the QP requires confidence that:
- The batch has been manufactured and tested according to approved requirements
- Importation testing has been completed and meets approved specifications
- Batch documentation and Certificates of Analysis (CoA) have been reviewed
- Any deviations, OOS results, investigations, and CAPAs have been appropriately assessed
- The supply chain and product traceability are adequately controlled
Delays or gaps in quality documentation can impact timely QP certification and product availability.
How Sciom Supports
Sciom supports QP certification and batch release activities by providing the required quality information and documentation to support informed QP decisions.
- GMP-compliant testing
- Comprehensive Batch/Packaging documentation review
- API/Excipients Details
- QMS review for overall Batch
- CMO GMP status
Our services provide QPs with the necessary quality information to support informed batch certification decisions.
5. Lack of Visibility During Testing Activities
In today’s pharmaceutical environment, timely access to accurate information is essential for effective decision-making. Many companies experience limited visibility once samples arrive at the UK laboratory, leading to repeated follow-ups and uncertainty around project progress.
Typical challenges include:
- Has the sample been received and testing initiated?
- Are testing results available or pending?
- Are additional documents or information required?
- What is the current batch status?
- When can the Certificate of Analysis (CoA) be issued and batch release activities proceed?
Without real-time visibility, teams may spend valuable time requesting updates, searching for documents, and coordinating information across multiple stakeholders.
How Sciom Supports
Sciom enables transparent communication and real-time visibility throughout the testing and batch release process through our secure Client Portal and dedicated project management approach.
The Sciom Client Portal provides clients with easy access to:
- Monitor project progress in one centralised platform
- Access relevant project documentation whenever required
- Track batch status from sample receipt through completion
- View and download approved Certificates of Analysis (CoAs)
- Communicate directly with the Sciom team through integrated messaging for faster query resolution
Our digital approach provides visibility across the complete workflow:
Sample Receipt → Testing → Review and Approval → Certificate of Analysis
By improving transparency, communication, and access to critical information, Sciom helps clients proactively manage supply planning, reduce administrative delays, and make informed decisions with confidence.
Conclusion
Successful pharmaceutical importation into the UK requires careful planning, robust quality systems, and reliable testing partners.
With expertise in UK MIA importation testing, QP release UK support, and pharmaceutical batch release services, Sciom helps companies overcome regulatory and operational challenges while maintaining the highest standards of quality and compliance.
Partner with Sciom to establish a reliable pathway for UK pharmaceutical supply from importation testing through to final batch release.
Frequently Asked Questions (FAQs)
- Sciom supports a broad range of pharmaceutical products, including:
- Tablets and capsules
- Oral liquids
- Creams and ointments
- Sterile products
References
- https://www.gmp-compliance.org/guidelines/gmp-guideline/eu-gmp-annex-16-certification-by-a-qualified-person-and-batch-release
- https://health.ec.europa.eu/document/download/e2ddfe65-7b4e-4765-b71b-4681772d2949_en
- https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
- https://mhrainspectorate.blog.gov.uk/2021/08/13/transfer-of-analytical-methods/